BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81. [PMID: 27634970 DOI: 10.1093/qjmed/hcw151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Elcioglu ZC, Reeves HL. NAFLD-which patients should have hepatocellular carcinoma surveillance? Hepatobiliary Surg Nutr 2017;6:353-5. [PMID: 29152488 DOI: 10.21037/hbsn.2017.06.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 da Silva CM, Caetano FH, Pereira FDC, Morales MAM, Sakane KK, Moraes KCM. Cellular and molecular effects of Baccharis dracunculifolia D.C. and Plectranthus barbatus Andrews medicinal plant extracts on retinoid metabolism in the human hepatic stellate cell LX-2. BMC Complement Altern Med 2019;19:222. [PMID: 31438947 DOI: 10.1186/s12906-019-2591-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Patten DA, Wilkinson AL, O'Rourke JM, Shetty S. Prognostic Value and Potential Immunoregulatory Role of SCARF1 in Hepatocellular Carcinoma. Front Oncol 2020;10:565950. [PMID: 34354939 DOI: 10.3389/fonc.2020.565950] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Huang SF, Chang IC, Hong CC, Yen TC, Chen CL, Wu CC, Tsai CC, Ho MC, Lee WC, Yu HC, Shen YY, Eng HL, Wang J, Tseng HH, Jeng YM, Yeh CT, Chen CL, Chen PJ, Liaw YF. Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatol Commun 2018;2:747-59. [PMID: 29881825 DOI: 10.1002/hep4.1182] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
5 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Reference Citation Analysis]
6 Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13:688-694. [PMID: 31701393 DOI: 10.1007/s12072-019-09995-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
7 Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017; 8(6): 429-436 [PMID: 29291167 DOI: 10.5306/wjco.v8.i6.429] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 48] [Article Influence: 10.4] [Reference Citation Analysis]
8 Granata V, Fusco R, Setola SV, Avallone A, Palaia R, Grassi R, Izzo F, Petrillo A. Radiological assessment of secondary biliary tree lesions: an update. J Int Med Res 2020;48:300060519850398. [PMID: 32597280 DOI: 10.1177/0300060519850398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537. [PMID: 30065915 DOI: 10.1155/2018/2784537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
12 Castellana M, Donghia R, Lampignano L, Castellana F, Zupo R, Sardone R, Pergola G, Giannelli G. Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma. J Clin Med 2021;10:4638. [PMID: 34682759 DOI: 10.3390/jcm10204638] [Reference Citation Analysis]